- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of February 11
The Center for Biosimilars® recaps the top news for the week of February 11, 2019.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 11.
Number 5: Samsung Bioepis has announced a new licensing agreement with the private equity firm C-Bridge Capital that will allow the drug maker to expand its reach into China.
Number 4: A recent Australian study found that infliximab reduces short-term costs versus colectomy in patients with acute severe ulcerative colitis, and biosimilars could drive costs down even more.
Number 3: A recent study examining Medicare Part D reimbursement policies for off-label uses found that coverage decisions could hamper patient access.
Number 2: In a long-running patent dispute, AbbVie has been ordered to produce documents related to its efforts to obtain patents to shield Humira from biosimilar competition.
Number 1: During a presentation at the Access! 2019 meeting, an IQVIA executive broke down market share data for US biosimilars.
Finally, last week, our e-newsletter asked whether you think that all biosimilars, not just interchangeable ones, should be substitutable at the pharmacy level.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
